The new ELISA was validated and then used to measure activin B levels in the circulation of healthy participants, IVF patients, pregnant women and in ovarian follicular fluid and seminal plasma.
Patients and measurements
Healthy adult subjects (n = 143), subjects from an IVF clinic (n = 27) and pregnancy groups (n = 29) were sampled.
The sensitivity of the assay was 0 center dot 019 ng/ml. Validation of the activin B ELISA showed good recovery (90 center dot 7 +/- 9 center dot 8%) and linearity in biological fluid and cell culture media and low cross-reactivity with related analytes (inhibin B = 0 center dot 077% and activin A = 0 center dot 0034%). There was a negative correlation between activin B concentration (r = -0 center dot 281, P < 0 center dot 011) and females with increasing age. Patients attending IVF clinics had significantly lower levels of activin B compared with gender-matched control subjects. Ovarian follicular fluid and seminal plasma had 50-80 fold higher levels of activin B (mean = 5 center dot 35 and 3 center dot 66 ng/ml respectively) than sera (mean = 0 center dot 071 ng/ml).
This fully validated ELISA for activin B offers a tremendous utility for measuring this protein in a variety of normal physiological processes and in various clinical pathologies..